Clinical

Dataset Information

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors


ABSTRACT: A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors

DISEASE(S): Ovarian Cancer,Endometrial Cancer,Solid Tumor,Nsclc,Colorectal Cancer,Endometrial Neoplasms,Hepatocellular Carcinoma

PROVIDER: 2369341 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR